Eight healthy paid male volunteers (age: 21–28 years, mean: 24.5 ± 1.7 years; weight 62–79 kg) were administered via intravenous infusion (3 min) acute 25-, 50-, and 75-mg doses of phosphatidylserine, or matching placebo in a latin-square design. Multichannel EEG recordings were performed in baseline conditions, during intravenous infusion, and 10, 30, 90, 180, and 360 min after drug/placebo administration. Blood pressure, heart rate, critical flicker-fusion frequency, and the subjects’ performance at immediate and short-term retention tests were assessed after each electroencephalographic (EEG) recording. The EEG signal was quantified offline by power spectral analysis, and bidimensional scalp maps were produced for each EEG variable. Descriptive statistical comparisons among subjects and between pre- and postdrug EEG recordings allowed the detection of systematic EEG changes (notably increment of the power on the ‘alpha’ frequency, which was restricted to the anterior electrode derivations at the 50-mg dose and widespread to the whole scalp at the highest dose, and increase of the signal total power) in the absence of significant modifications of the subjects’ neuropsychological status.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.